0
0
New Delhi, 10th July 2024 – The 7th India-Japan Medical Product Regulatory Symposium, organized by the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare, Government of India, successfully convened at the FICCI Convention Hall. This significant event, conducted in accordance with the Memorandum of Cooperation (MoC) between India and Japan, underscored the ongoing commitment to fostering collaboration in medical product regulations.
The symposium saw the participation of approximately 200 delegates, including representatives from the Ministry of Health & Family Welfare, India, and the Ministry of Health, Law and Welfare, Japan. Attendees comprised 80 drug regulators and 120 industry representatives from both countries, creating a robust platform for knowledge exchange on Pharma, Medical Devices, and Regenerative Medicines.
The MoC, initially signed in December 2015 between CDSCO and the Ministry of Health, Labour and Welfare (MHLW) along with the Pharmaceutical and Medical Devices Agency (PMDA) of Japan, highlights mutual cooperation in medical product regulations until December 2025. These regulatory symposiums are held alternately in India and Japan, serving as crucial venues for exchanging insights and enhancing regulatory practices.
Esteemed dignitaries, including Shree Rajiv Wadhawan, Joint Secretary, MoHFW, Dr. Rajeev Singh Raghuvanshi, DCGI, CDSCO, Mr. Yada Shinji, Executive Director, PMDA, Dr. Hirota Mitsue, Deputy Director, MHLW, and Dr. Ranga Chandrashekar, JDCI, CDSCO, graced the inaugural session. Their presence underscored the importance of bilateral cooperation in advancing medical product regulations.
The symposium featured insightful presentations by Indian and Japanese Drug Regulatory Authorities, followed by in-depth discussions on emerging topics in Pharma, Medical Devices, and Regenerative Medicines. These deliberations were pivotal in updating industry stakeholders on the latest regulatory initiatives in both countries, ensuring that the medical products meet the highest standards of safety and efficacy.
This year’s symposium facilitated fruitful exchanges on regulatory updates and best practices, reinforcing the commitment to mutual growth and cooperation in the field of medical products. The continued collaboration between India and Japan through such symposiums is expected to pave the way for more robust regulatory frameworks, ultimately benefiting public health and safety.
The event concluded with a reaffirmation of the shared goals of India and Japan in enhancing medical product regulations and the anticipation of continued successful collaborations in the future.
